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Introduction. Pleomorphic giant cell pancreatic cancer is a very rare and aggressive pancreatic neoplasm. A case of pleomorphic
giant cell pancreatic cancer presenting as a cystic lesion and in association with a serous cystadenoma presents a unique case
which has not been described before. Case Presentation. A 44-year-old alcoholic man presented with abdominal pain, vomiting,
and weight loss. Initially, imaging suspected a pancreatic pseudocyst measuring 4.2cm. Endoscopic ultrasound- (EUS-) guided
ﬁne-needle aspiration revealed a serous cystadenoma. With conservative intervention only (ﬂuid resuscitation, analgesia, and
antiemetics) the patient improved and was discharged under close observation. Follow-up scan at four months revealed minimal
change. Three months later, he was admitted acutely. Repeat scans demonstrated mild cyst enlargement with new liver lesions.
Laparoscopic biopsy revealed pleomorphic giant cell carcinoma with the organ of origin the pancreas. Conclusion.T h i su n u s u a l
case highlights the challenges in managing pancreatic cystic lesions and emphasizes the importance of considering less common
forms of pancreatic cystic masses when the ﬁndings are atypical for the presentation. Surgical excision in these cases over
conservative steps may be the most appropriate management.
1.Introduction
Giant cell pancreatic cancer was ﬁrst described by Sommers
and Meissner in 1954 [1]. In the literature, these rare
tumours have been divided into two subtypes: osteoclast-
like giant cell and pleomorphic giant cell carcinoma of the
pancreas.Althoughanumberofreviewshaveshown possible
prognostic diﬀerences between these two subtypes, the most
recent World Health Organisation (WHO) classiﬁcation
places the neoplams in the same category, undiﬀerentiated
carcinoma with osteoclast like giant cells [2]. In any case,
unless detected early, the majority of cases have a very poor
prognosis often worse than pancreatic adenocarcinoma [3].
In this report, we review the literature in the area and
present a unique case of a patient with known alcohol abuse
who developed metastatic pleomorphic giant cell cancer of
the pancreas within months of a diagnosis of a pancreatic
serous cystadenoma. The case also highlights the challenges
in managing pancreatic cystic lesions and emphasizes the
importance in considering rare forms of pancreatic cystic
masses when the ﬁndings are atypical for the presentation.
2.Case Report
A 44-year-old man, who was a known alcoholic, presented to
the First Department of Surgery, University of Athens with
symptoms of epigastric abdominal pain, vomiting, and2 HPB Surgery
weight loss. Clinical examination demonstrated mild ten-
derness throughout, but no masses were noted. Biochemical
analysis revealed Alanine aminotransferase (ALT) 172U/L,
Gamma-glutamyl transpeptidase (γ-GT) 163U/L, alkaline
phosphates (ALP) 464U/L, and C-reactive protein (CRP)
84.90mg/L. The serum levels of various tumour markers
were not increased: Alfa Feto Protein (AFP) 1.6, Carbohy-
drateAntigen19-9(CA19-9)12.3,CarbohydrateAntigen72-
4 (CA72-4) 1.8, and Carcinoembryonic Antigen (CEA) 3.6.
A subsequent computed tomography (CT) scan revealed
the presence of a 4cm × 4.2cm cystic lesion in the body
and tail of the pancreas. There was also a minor increase in
diameter of the peripheral segment of the pancreatic duct
and disseminated damage of the pancreatic parenchyma,
suggestive of multiple episodes of pancreatitis in the past.
There was no ascites or any other suspicious ﬁndings from
the scan. Fine-needle aspiration biopsies with endoscopic
ultrasound guidance (EUS) of the pancreatic lesion were
performed. The biochemical analysis was positive for amy-
lase (23,000U/L), and cytology was consistent with the
diagnosis of a serous cystadenoma. Tumour markers (CEA,
AFP, and CA 19-9) were negative. The patient’s symptoms
subsequentlyimproved with conservative management only:
ﬂuid resuscitation, analgesia, and antiemetics. Drainage of
the cyst itself was not performed. Six days after admission,
the patient was discharged with outpatient followup with
repeat scanning. Four months followed without symptoms,
and a second CT scan indicated only a small increase
(4cm × 4.5cm) in the pancreatic cystic lesion. No other
abnormalities were detected from the scan.
Three months later the patient presented acutely with
recurrence of severe epigastric abdominal pain. Biochemical
analysis again demonstrated deranged liver function and
elevatedinﬂammatory markers. Tumour markers were nega-
tive.A repeatCTinadditiontoMagnetic ResonanceImaging
(MRI) and Magnetic Resonance Cholangiopancreatography
(MRCP) revealed only marginal enlargement in the pancre-
atic cystic lesion, but now there were also multiple lesions in
the liver ranging from a few milimetres to 2.5cm in diameter
(Figure 1). The patient underwent laparoscopy and biopsy
which revealed inﬁltration of the liver tissue by a giant cell
carcinoma. The neoplastic cells were anaplastic or spindle
often acquiring giant cell features. The growth pattern was
diﬀuse with pseudospaces, and the stroma was loose and
abundant with inﬂammatory inﬁltrates (Figures 2(a) and
2(b)).Theneoplasticcellsshowedcytokeratin7(Figure 3(a))
and cytokeratin 19 (Figure 3(b)) immunopositivity. The
morphological and immunohistochemical features from the
hepatic, pancreatic, and lymph node biopsies revealed the
diagnosis of pleomorphic giant cell carcinoma, with the
o r g a no fo r i g i nt h ep a n c r e a s .A tt h i sa d v a n c e ds t a g e ,s u r g i c a l
resection was not possible and the patient died four months
later.
3.Discussion
Cystic lesions of the pancreas are an increasingly common




Figure 1: Pancreatic lesion and liver metastases on CT.
pancreaticcysticneoplasmsremain rareandaccountforonly
10%–15% of these cysts [4, 5]. Once identiﬁed, the initial
step in managing cystic lesions is diﬀerentiating a pancreatic
pseudocyst from a cystic neoplasm. A careful review of
the clinical background of the patient is paramount, with
previous documented pancreatitis or identiﬁable risk factors
for pancreatitis (chronic alcohol consumption, history of
gall stones, or a strong family history of pancreatitis)
an essential starting point. If these factors are present
the cystic lesion is more likely a pseudocyst, but it may
also be the ﬁrst presentation of a neoplastic lesion. The
patient demographics, and the cyst size, site, and quantity
provide valuable information in predicting the nature of the
lesion [5]. Ultimately a combination of CT, MRI, MRCP,
Endoscopic retrograde cholangiopancreatography (ERCP),
or EUS with biopsy provides the diagnosis in most cases,
with EUS the most fashionable approach at present [6–8].
The patientinthis reportwas a44-year-oldmale withknown
excess alcohol consumption, and CT ﬁndings are consistent
with previous pancreatitis. Although the clinical features
were suggestive of a pseudocyst, an EUS with biopsy was
performed and while the amylase was elevated, the cytology
suggested a serous cystadenoma.
Serous cystadenomas are largely benign lesions which
present more frequently in middle aged/elderly females
without a history of pancreatitis are evenly distributed
throughout the pancreatic gland and have a low amylase
leveland low tumourmarkers (speciﬁcally CEA)[9, 10]. The
clinicalfeaturesinourcasedidnotconformtotheseﬁndings.
It is worthwhile noting however that the diagnostic accuracy
of CT for pancreatic cysts has been reported to range
from 20–90% and the sensitivity for analyzing pancreatic
cystic ﬂuid shows a range from 50–93% [11–13]. In this
instance, the patient clinically improved and with cytology
demonstrating a serous cystadenoma; close observation was
deemed the most appropriate management. Interestingly,
Tseng et al. recommend excision of large (>4cm) serous
cystadenomas irrespective of symptoms, which goes against
the management of this 4.4cm cyst [14].
Although serous cystadenomas are considered eﬀectively
benign, there have been a number of single-case reports
highlighting the presence of malignant features [15, 16].
However, there are no reported cases in the English literatureHPB Surgery 3
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Figure 2: Histological section of the liver biopsy that demonstrates inﬁltration by a giant cell carcinoma with a diﬀuse growth pattern. The
neoplastic cells line also pseudospaces due to lack of cohesiveness. (H & E counterstain, magniﬁcation x200).
(a) (b)
Figure 3: Representative immunohistochemical results. Cytokeratin 7 (a) and cytokeratin 19 (b). DAB immunohistochemistry performed
by an indirect streptavidin-biotin-peroxidase method on paraﬃn section counterstained with haematoxylin. (magniﬁcation x400).
of a coexistent serous cystadenoma and giant cell pancreatic
cancer, as was the case here.
Giant cell pancreatic cancer is a rare neoplasm, char-
acterised by the presence of giant cells, hypervascularity,
and an inﬂammatory response [17]. It accounts for 2%–
12.8% of all cases of pancreatic malignancies, and despite
active intervention, patients usually die within months of
diagnosis [17]. The neoplasm has been subdivided into two
groups, osteoclast-like and pleomorphic giant cell pancreatic
cancer. Indeed, a third grouping, known as mixed type,
has highlighted the possibility that these tumours may
indeed represent a morphological spectrum with osteoclast-
like giant cell tumours at one end and pleomorphic giant
cell tumours at the other [18]. Classic osteoclast-like giant-
cell tumours have a predominant population of osteoclast-
like giant cells and abundant hemosiderin granules whereas4 HPB Surgery
pleomorphic giant cell pancreatic neoplasms have more ple-
omorphic multinucleated giant-cells and mononuclear cells
[19].
The clinical features of pleomorphic giant cell carcinoma
are comparable to those of pancreatic adenocarcinoma with
abdominal pain and weight loss the most prevalent [17, 20].
Cancer site has a role to play here, with head of pancreas
cancers presenting more frequently with jaundice. Although
there does not appear to be a preferred pancreatic site, even
though some studies report higher prevalence in the body
and tail. The mean age of onset is 65 years, and there appears
to be a male predominance. Elevated inﬂammatory markers
are present in the majority of cases, and CT ﬁndings often
show large irregular hypodense masses (majority >6cm)
[17, 19, 20]. The survival range for pleomorphic giant cell
pancreatic cancer ranges from several weeks in advanced
unresectable disease to 25 months [21, 22]. The osteoclast-
like giant cell variant may have a better prognosis (due to
reducedprevalenceofmetastasis), butthe evidencefor thisis
inconclusive [20, 22, 23].
There have been at least two reported cases of osteoclast-
like giant cell pancreatic tumours presenting as pseudocyst
lesions and a similar number as mucinous cystadenomas
[24–26]. There has been one case of a mixed (osteoclast-
likeand pleomorphic)giantcellpancreatic cancerpresenting
as a pseudocyst [27]. There have been no reported cases of
an association between serous cystadenoma and any form of
giant cell pancreatic cancer, which we report here.
The diagnostic accuracy of CT, EUS with biopsy and
cytology is quite high, depending on the papers cited [6–
9]. However, it is more than possible for a neoplastic cyst
to be missed on a single biopsy, which is plausible in the
case here. However, considering the clinical improvement in
the patient’s condition, background history of alcohol excess
+/− episodes of pancreatitis and stable disease on repeat
scanning, the role of conservative management could be jus-
tiﬁed. It may also be suggested that in the eight months from
initial diagnosis an aggressive pleomorphic giant cell cancer
may have developed at or near the site of the presumed
cystadenoma rather than a direct association between the
two. The management of this case may have been diﬀerent
on reﬂection of the radiological and cytological ﬁndings
considering the clinical background of the patient. Surgical
resection at the initial presentation may have identiﬁed the
neoplasm and altered the outcome for the patient. Overall
the case emphasizes the challenge in managing pancreatic
cystic lesions and suggests lowering the threshold for surgical
resection in atypical cases.
4.Conclusion
The report discusses an unusual case of pleomorphic giant
cell cancer of the pancreas which presented initially as
a pancreatic cystic lesion and was diagnosed as a serous
cystadenoma.The casehighlights thechallenges inmanaging
pancreatic cystic lesions and emphasizes the importance of
considering less common forms of pancreatic cystic masses
when theﬁndings are atypicalwiththe presentation.Surgical
excision in these cases over conservative steps may be the
most appropriate management.
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